Alembic Pharmaceuticals Limited has informed the Exchange about change in Management - Relinquishment of the position of Chief Financial Officer of the Company
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. R. K. Baheti, who served as Director – Finance and Chief Financial Officer, has stepped down from the CFO role effective 7th July 2025. He will continue to serve on the board as an Executive Director, as per his existing terms of appointment. In his letter to the board, Mr. Baheti described this as a planned succession within the finance function and thanked the board for asking him to continue. The company has not announced a replacement CFO in this filing.
The change appears orderly and pre-planned rather than abrupt, and continuity is preserved through Mr. Baheti's continued presence as Executive Director. Investors may look for clarity on who will take over the CFO role, as an unfilled finance leadership position could create short-term uncertainty until a successor is named.